H.R. 7528: Growing America’s Pharmaceutical Supply Act

This bill, known as the Growing America’s Pharmaceutical Supply Act, aims to address drug shortages by modifying certain provisions of the Federal Food, Drug, and Cosmetic Act. Specifically, it seeks to amend Section 503B of this act, allowing outsourcing facilities—which are organizations that compound and distribute drugs—to continue supplying medications to the market for a short period after a drug is declared in shortage.

Key Provisions

• The bill proposes a "tail period" that allows outsourcing facilities to compound and distribute drugs that are in shortage for up to 180 calendar days after the shortage is identified.
• This amendment replaces the current language that requires such actions to occur "at the time" of the shortage declaration, making it more flexible for these facilities.
• The aim of this change is to enhance the capability of outsourcing facilities to respond to drug shortages, thereby supporting a more stable pharmaceutical supply chain.

Implications

By extending the timeframe in which outsourcing facilities can supply drugs after a shortage is declared, the legislation aims to:

• Mitigate potential disruptions in medication availability for patients.
• Provide a more reliable mechanism for healthcare providers to obtain critical medications during shortages.

Relevant Companies

• PFE (Pfizer Inc.): As a major pharmaceutical company, Pfizer could be affected by the changes in how drugs are compounded and distributed, especially if they experience significant shortages of their products.
• MRK (Merck & Co., Inc.): Merck, also a leading pharmaceutical manufacturer, might see implications in the way shortages are managed within the outsourcing facilities that deal with their drugs.
• AMGN (Amgen Inc.): Amgen, which produces a variety of medications, may be impacted as the bill influences the supply dynamics related to essential therapeutic drugs.